Patents by Inventor Dov Michaeli

Dov Michaeli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8388966
    Abstract: A combination for use in the treatment of pancreatic cancer comprising: (i) an anti-gastrin effective immunogenic composition; and, (ii) one or more chemotherapeutic agents suitable for inhibiting cancer growth.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: March 5, 2013
    Assignee: Cancer Advances, Inc.
    Inventors: Philip C. Gevas, Dov Michaeli, Stephen Grimes, Martyn Caplin
  • Patent number: 8343930
    Abstract: The present invention relates to a combination therapy method for treating gastrin-dependent tumors. The method comprises the immunization of a patient with an anti-gastrin 17 immunogenic composition in combination with the administration of chemotherapeutic agents such as 5-fluorouracil and leucovorin.
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: January 1, 2013
    Assignee: Cancer Advances, Inc.
    Inventors: Philip C. Gevas, Stephen Grimes, Stephen L. Karr, Susan A. Watson, Dov Michaeli
  • Publication number: 20110117108
    Abstract: The invention relates to the treatment and/or prevention of cancerous and/or, precancerous conditions of the liver, lung and esophagus by actively and/or passively immunizing a patient against the peptide hormone gastrin and/or a gastrin receptor, e.g., the CCK-B/gastrin receptor. The immunizations of the invention may be employed as a monotherapy, an adjunctive therapy, or as part of a combination therapy.
    Type: Application
    Filed: January 24, 2011
    Publication date: May 19, 2011
    Applicant: Cancer Advances, Inc.
    Inventors: Philip C. Gevas, Dov Michaeli, Stephen Grimes
  • Publication number: 20100129382
    Abstract: The present invention relates to a combination therapy method for treating gastrin-dependent tumors. The method comprises the immunization of a patient with an anti-gastrin 17 immunogenic composition in combination with the administration of chemotherapeutic agents such as 5-fluorouracil and leucovorin.
    Type: Application
    Filed: January 25, 2010
    Publication date: May 27, 2010
    Inventors: Philip C. Gevas, Stephen Grimes, Stephen L. Karr, Susan A. Watson, Dov Michaeli
  • Publication number: 20090191232
    Abstract: The present invention relates to a combination therapy method for treating gastrin-dependent tumors. The method comprises the immunization of a patient with an anti-gastrin 17 immunogenic composition in combination with the administration of chemotherapeutic agents such as 5-fluorouracil and leucovorin.
    Type: Application
    Filed: November 25, 2008
    Publication date: July 30, 2009
    Inventors: Philip C. Gevas, Stephen Grimes, Stephen L. Karr, Susan A. Watson, Dov Michaeli
  • Publication number: 20090004200
    Abstract: A combination for use in the treatment of pancreatic cancer comprising: (i) an anti-gastrin effective immunogenic composition; and, (ii) one or more chemotherapeutic agents suitable for inhibiting cancer growth.
    Type: Application
    Filed: August 8, 2008
    Publication date: January 1, 2009
    Inventors: Philip C. Gevas, Dov Michaeli, Stephen Grimes, Martyn Caplin
  • Publication number: 20070184064
    Abstract: Chimeric peptide epitopes can serve as effective immunogens against hormones and other small peptides or proteins. Thus, immunogenic peptides are selected from promiscuous Th epitopes and synthesized together with self antigenic peptide sequences fused with or without end to end spacer peptide interconnections. A peptide sequence which may be of the gonadotropin releasing hormone is linked with an immunogenic peptide sequence selected from a promiscuous Th-epitope of measles virus protein F, tetanus toxoid, or malaria protein CSP. Compositions of the chimeric immunogen are found effective in eliciting high and specific anti-GnRH antibody titers.
    Type: Application
    Filed: July 6, 2004
    Publication date: August 9, 2007
    Inventors: Stephen Grimes, Dov Michaeli, Vernon Stevens
  • Publication number: 20070082043
    Abstract: The invention provides liposomal vehicles for encapsulating relatively high levels of water-soluble substances including immunogens directed against gastrin and gonadotropin releasing hormone. The liposome encapsulating large amounts of immunogens can be injected parentally to induce effective immune responses without exhibiting significant adverse tissue reactogenicity.
    Type: Application
    Filed: July 25, 2006
    Publication date: April 12, 2007
    Inventors: Dov Michaeli, Stephen Grimes, Yechezkel Barenholz, Simcha Even-Chen
  • Publication number: 20070065454
    Abstract: The invention provides liposomal vehicles for encapsulating relatively high levels of water-soluble substances including immunogens directed against gastrin and gonadotropin releasing hormone. The liposome encapsulating large amounts of immunogens can be injected parentally to induce effective immune responses without exhibiting significant adverse tissue reactogenicity.
    Type: Application
    Filed: July 20, 2006
    Publication date: March 22, 2007
    Inventors: Dov Michaeli, Stephen Grimes, Yechezkel Barenholz, Simcha Even-Chen
  • Publication number: 20060140962
    Abstract: A combination for use in the treatment of pancreatic cancer comprising: (i) an anti-gastrin effective immunogenic composition; and, (ii) one or more chemotherapeutic agents suitable for inhibiting cancer growth.
    Type: Application
    Filed: February 22, 2006
    Publication date: June 29, 2006
    Inventors: Philip Gevas, Dov Michaeli, Stephen Grimes, Martyn Caplin
  • Publication number: 20060039911
    Abstract: A method for the treatment of gastroesophageal reflux disease comprising a combination of active immunization with an anti-gastrin immunogenic composition with an antagonist that blocks or inhibits gastric acid pump activity; or alternatively administering purified anti-gastrin antibodies with an H2 antagonist or proton pump inhibitor of the gastric acid producing enzyme system.
    Type: Application
    Filed: October 18, 2005
    Publication date: February 23, 2006
    Applicant: Aphton Corporation
    Inventors: Philip Gevas, Stephen Grimes, Stephen Karr, Dov Michaeli
  • Publication number: 20050187152
    Abstract: Serum-associated hypergastrinemia is treated by administration of gastrin active or passive immunization. An anti-gastrin immunogenic composition containing a gastrin G17 or G34 peptide fragment which is amino acid spacer-linked to an immunogenic carrier, is administered so as to effectively neutralize the circulating gastrin hormone, and moreover, inhibit autocrine activity by progastrin such as Gly-extended G17, and amidated G17, in patients with pernicious anemia. Moreover, the method includes administration of a therapeutically effective amount of anti-G17 or anti-G34 antibodies which may be in humanized form. Finally, the method provides ameliorating treatment of hypergastrinemic effects of proton pump inhibitors or H2 histamine receptor blocking agents or antagonists, in addition to treatment of hypergastrinemia caused by diseases such as pernicious anemia.
    Type: Application
    Filed: April 21, 2004
    Publication date: August 25, 2005
    Applicant: Aphton Corporation
    Inventors: Philip Gevas, Stephen Grimes, Stephen Karr, Dov Michaeli, Susan Watson
  • Publication number: 20050169979
    Abstract: The invention provides liposomal vehicles for encapsulating relatively high levels of immunogenic protein substances including immunogens directed against hormones and hormone receptors, such as gastrin and gonadotropin releasing hormone and their receptors. The liposome encapsulating large amounts of immunogens can be injected parenterally to induce effective immune responses without exhibiting significant adverse tissue reactogenicity. Methods for production of the liposomal vaccines and methods of their administration for treatment of diseases and conditions associated with the cognate hormones are also provided.
    Type: Application
    Filed: January 14, 2005
    Publication date: August 4, 2005
    Inventors: Dov Michaeli, Stephen Grimes, Yechezkel Barenholz, Simcha Even-Chen, Susan Hagan
  • Publication number: 20050112721
    Abstract: Chimeric peptide epitopes can serve as effective immunogens against hormones and other small peptides or proteins. Thus, immunogenic peptides are selected from promiscuous Th epitopes and synthesized together with self antigenic peptide sequences fused with or without end to end spacer peptide interconnections. A peptide sequence which may be of the gonadotropin releasing hormone is linked with an immunogenic peptide sequence selected from a promiscuous Th-epitope of measles virus protein F, tetanus toxoid, or malaria protein CSP. Compositions of the chimeric immunogen are found effective in eliciting high and specific anti-GnRH antibody titers.
    Type: Application
    Filed: August 31, 2004
    Publication date: May 26, 2005
    Inventors: Stephen Grimes, Dov Michaeli, Vernon Stevens
  • Publication number: 20050025770
    Abstract: A method of treating gastrointestinal cancers dependent on the prohormones amidated gastrin-17 and glycine extended G-17, comprising the administration to the patient of an anti-gastrin 17 immunogen which induces antibodies which bind and neutralize amidated and glycine-extended gastrin-17.
    Type: Application
    Filed: January 20, 2004
    Publication date: February 3, 2005
    Inventors: Philip Gevas, Stephen Karr, Stephen Grimes, Dov Michaeli, Susan Watson
  • Publication number: 20040247661
    Abstract: The invention provides liposomal vehicles for encapsulating relatively high levels of water-soluble substances including immunogens directed against gastrin and gonadotropin releasing hormone. The liposome encapsulating large amounts of immunogens can be injected parentally to induce effective immune responses without exhibiting significant adverse tissue reactogenicity.
    Type: Application
    Filed: January 15, 2004
    Publication date: December 9, 2004
    Inventors: Dov Michaeli, Stephen Grimes, Yechezkel Barenholz, Simcha Even-Chen
  • Publication number: 20040208920
    Abstract: The invention provides liposomal vehicles for encapsulating relatively high levels of water-soluble substances including immunogens directed against gastrin and gonadotropin releasing hormone. The liposome encapsulating large amounts of immunogens can be injected parentally to induce effective immune responses without exhibiting significant adverse tissue reactogenicity.
    Type: Application
    Filed: July 3, 2003
    Publication date: October 21, 2004
    Inventors: Dov Michaeli, Stephen Grimes, Yechezkel Barenholz, Simcha Even-Chen
  • Patent number: 6783761
    Abstract: Chimeric peptide epitopes can serve as effective immunogens against hormones and other small peptides or proteins. Thus, immunogenic peptides are selected from promiscuous Th epitopes and synthesized together with self antigenic peptide sequences fused with or without end to end spacer peptide interconnections. A peptide sequence which may be of the gonadotropin releasing hormone is linked with an immunogenic peptide sequence selected from a promiscuous Th-epitope of measles virus protein F, tetanus toxoid, or malaria protein CSP. Compositions of the chimeric immunogen are found effective in eliciting high and specific anti-GnRH antibody titers.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: August 31, 2004
    Assignee: Aphton Corporation
    Inventors: Stephen Grimes, Dov Michaeli, Vernon C. Stevens
  • Publication number: 20040001842
    Abstract: The invention concerns immunogens, immunogenic compositions and method for the treatment of gastrin-dependent tumors. The immunogens comprise a gastrin receptor immunomimic peptide conjugated to an immunogenic carrier. The immunogens are capable of inducing antibodies in vivo which bind to the gastrin-receptor (GR) in gastrin responsive malignant or premalignant tumor, thereby preventing growth stimulating peptide hormones from binding to the receptors, and inhibiting tumor cell growth. The invention also comprises specific antibodies against the gastrin-receptor for passive immunization. Furthermore, the invention comprises cytotoxic molecule derivatized anti-GR antibodies. The invention also concerns diagnostic methods for detecting gastrin-dependent tumors in vivo or from a tissue biopsy using the antibodies of the invention. Active and passive immunization can be combined providing an immune response against GR, G17 and/or G17-Gly.
    Type: Application
    Filed: December 19, 2002
    Publication date: January 1, 2004
    Inventors: Dov Michaeli, Martyn Caplin, Susan A. Watson, Stephen Grimes
  • Publication number: 20030091574
    Abstract: A combination for use in the treatment of pancreatic cancer comprising:
    Type: Application
    Filed: March 22, 2002
    Publication date: May 15, 2003
    Inventors: Philip C. Gevas, Dov Michaeli, Stephen Grimes, Martyn Caplin